Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ASPH | Q12797 | 2/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.50 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782531 | 0.90 | MAPT (0.58) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL3255746 | 0.89 | AURKA (0.55) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL4847270 | 0.86 | GAA (0.53) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL29467955 | 0.79 | GAA (0.52) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL28707454 | 0.79 | GAA (0.52) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL27033961 | 0.79 | NPC1 (0.60) | KDM4EASPHKDM8MAPTGAA | |
| SCHEMBL29467971 | 0.78 | CA12 (0.49) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL28714008 | 0.78 | CA12 (0.49) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL870110 | 0.77 | P4HTM (0.55) | VNN1KDM4EASPHKDM8RIOX2 | |
| SCHEMBL14195182 | 0.77 | KDM4E (0.51) | VNN1KDM4EASPHKDM8RIOX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | VNN1 257/4885KDM4E 1906/4885ASPH 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.